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Upon binding to pathogen or self-derived cytosolic nucleic acids cyclic GMP-AMP
synthase (cGAS) triggers the production of cGAMP that further activates transmembrane
protein STING. Upon activation STING translocates from ER via Golgi to vesicles.
Monogenic STING gain-of-function mutations cause early-onset type I interferonopathy,
with disease presentation ranging from fatal vasculopathy to mild chilblain lupus.
Molecular mechanisms underlying the variable phenotype-genotype correlation are
presently unclear. Here, we report a novel gain-of-function G207E STING mutation
causing a distinct phenotype with alopecia, photosensitivity, thyroid dysfunction,
and features of STING-associated vasculopathy with onset in infancy (SAVI), such
as livedo reticularis, skin vasculitis, nasal septum perforation, facial erythema, and
bacterial infections. Polymorphism in TMEM173 and IFIH1 showed variable penetrance
in the affected family, implying contribution to varying phenotype spectrum. The
G207E mutation constitutively activates inflammation-related pathways in vitro, and
causes aberrant interferon signature and inflammasome activation in patient PBMCs.
Treatment with Janus kinase 1 and 2 (JAK1/2) inhibitor baricitinib was beneficiary for
a vasculitic ulcer, induced hair regrowth and improved overall well-being in one patient.
Protein-protein interactions propose impaired cellular trafficking of G207E mutant. These
findings reveal the molecular landscape of STING and propose common polymorphisms
in TMEM173 and IFIH1 as likely modifiers of the phenotype.
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INTRODUCTION
Monogenic interferonopathies are characterized by increased
type I interferon (IFN) signaling leading to vasculopathy,
autoinflammation, and systemic lupus erythematosus (SLE)-like
disease (1). In these, increased sensing of endo- and exogenous
nucleic acids leads to hyperactive Toll-like-receptors (TLRs),
RNA and DNA sensors, and to an enhanced type I IFN response
(2), thought to maintain the persistent self-directed immune
reaction (3).
One currently known monogenic interferonopathy is STING-
associated vasculopathy with onset in infancy (SAVI), caused by
mutations in TMEM173 (4, 5). TMEM173 encodes stimulator
of interferon genes (STING), a transmembrane protein residing
in the endoplasmic reticulum (ER). It senses cytosolic double
stranded DNA (dsDNA) and directly binds to bacterial second
messengers, such as cyclic dinucleotides (CDNs) c-di-GMP, c-
di-AMP, and 3′3′-cGAMP (6, 7). The recognition of nucleic
acids or cyclic nucleotides initiates the production of type I
IFN and other inflammatory cytokines leading to nucleic-acid
driven inflammation.
STING has four amino-terminal transmembrane domains
spanning the first 136 amino acids, followed by the helix α1
at residues 153-177 (8). Helix α1, or the dimerization domain,
is essential for protein stability, intraprotein interactions, and
ligand binding (9). The CDN binding domain (residues 153-
340) is part of the cytoplasmic carboxy-terminus having
multiple phosphorylation and downstream signaling interaction
sites (8, 10).
The first described constitutively active TMEM173 mutations
are situated at or near the helix α1 and associated with early-
onset vasculitis, autoinflammation, and interstitial lung disease
defining the SAVI phenotype (5, 11, 12). A recent study identified
five patients with a gain-of-function (GOF) mutation affecting
the dimerization domain (13). In contrast to the severely affected
infants (5) these patients presented with mild skin vasculitis
and were diagnosed with familial chilblain lupus (13). Also
proximal substitutions affecting the CDN binding domain were
reported in single patients presenting with variable phenotypes
of STING-associated autoinflammation (14, 15). Overall, all of
the reported TMEM173 mutations have been GOF, leading to
elevated IFN-β production activating the JAK/STAT-pathway
and generating a positive feedback loop (16). As there is poor
correlation between genotype and clinical phenotype, poorly
understood intrinsic or environmental factors likely modify the
disease outcome.
Another important interferonopathy gene is the IFN-induced
helicase C domain-containing protein 1 (IFIH1, also known
as MDA5). IFIH1 functions as a nucleic acid sensor in the
Abbreviations: 2′3′-cGAMP, cyclic GMP-AMP, mammalian cGAMP (tlrl-
nacga23); 3′3′-cGAMP, cyclic GMP-AMP, bacterial cGAMP (tlrl-nacga); cGAS,
cyclic GMP-AMP synthase; c-di-GMP, cyclic di-guanylate monophosphate (tlrl-
nacdg); CDN, cyclic-di-nucleotide; FCL, familial chilblain lupus; GOF, gain-of-
function; IFIH1, interferon induced with helicase C domain 1; SAVI, STING-
associated vasculopathy with onset in infancy; SLE, systemic lupus erythematosus;
SMS, Singleton-Merten syndrome; STING, Stimulator of interferon genes protein;
TMEM173, transmembrane protein 173.
cytoplasm, inducing transcription of type I IFN and IFN-
regulated genes upon activation. GOF IFIH1 variants are
seen in Aicardi-Goutières and Singleton-Merten syndromes
(17–19). Also, polymorphism in IFIH1 has been linked to SLE
(rs1990760, p.Ala946Thr, A946T) (20, 21) leading to a variable
phenotype spectrum (22). The A946T GOF risk variant leads to
increased production of type I IFN, promoting inflammation and
increasing the risk of autoimmunity. It also modifies the effects
of other autoimmune risk alleles, which leads to variable disease
severity (23, 24). Interestingly, a haplotype consisting of IFIH1
T946 allele and R843 allele (rs3747517, p.His843Arg, H843R)
has been reported to associate with risk of type I diabetes and
psoriasis (24), but to be protective for chronic periodontitis (25).
Here we report a large family, presenting with several lupus-
like features and features of SAVI (Table 1). We propose that
the variable interplay of novel disease-causing G207E mutation
and known polymorphism in TMEM173 affects the disease
phenotype together with IFIH1 risk alleles. Our results broaden
the spectrum of TMEM173 mutation-associated phenotypes,
provide insight into the activation of alternative NLRP3
inflammasome and reveal the STING interactome.
MATERIALS AND METHODS
Ethics, Consent, and Permissions
The study was conducted in accordance to the principles
of the Helsinki Declaration and was approved by the
Helsinki University Central Hospital Ethics Committee
(91/13/03/00/2011). Written informed consent was obtained
from the patients and healthy controls.
Consent to Publish
Written informed consent was obtained from the patients and
healthy controls (or legal guardian for child) to publish individual
patient data including images.
Patient Information
From birth, the index case IV.1 (Figure 1) has had erythema
on the cheeks and severe livedo reticularis on his body and
extremities, most pronounced on his sides, thighs, upper arms,
hips, and buttocks. Later, remitting idiopathic thrombocytopenia
and unspecified nail changes were noted at age 7 years,
as well as alopecia areata. Later, alopecia universalis with
sparing of genital, eyebrow and some scalp hair has developed.
Repeated bone marrow aspirates and karyotype have been
normal. He has nasal septal perforation and slightly dysmorphic
features with hypoplastic alae nasi and deep philtrum. He
is sensitive to UV radiation and burns extremely easily. He
was admitted to the dermatology ward at age 29 years due
to painful necrotic ulcerations resembling vasculitis on the
shin and ankle that had appeared after a sunburn. Skin
biopsy confirmed cutaneous vasculitis but extended laboratory
tests were normal, except for an elevated Factor VIII (192–
211%), considered an independent risk factor for venous
thrombosis (Figure 1E). His vasculitis was first treated with
prednisolone (from 0.8 mg/kg and tapered down) combined with
azathioprine (150mg, 1.5 mg/kg) or methotrexate (20 mg/week,
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TABLE 1 | Patient demographics and clinical features of affected family members.
Patient IV.l V.2 III.4 III.9 III.7 IV.6
Patient demographics
Age of symptom onset
(years)
Birth Birth Birth 4 8 10
Age at evaluation (years) 37 12 52 49 56 31
Gender Male Female Female Female Female Female
STING p.G207E G/E G/E G/E G/E G/E G/E
STING p.R232H rs1131769 R/H R/H R/H H/H H/H R/H
IFIH1-risk allele p.A946T
rs1990760
A/T T/T A/T A/T A/A A/A
IFIH1-risk allele p.H843R
rs3747517
R/R R/R R/R R/R H/R H/H
Inflammatory manifestations
Livedo reticularis Widespread birth Widespread birth Localized birth Widespread
adulthood
Widespread 8
years
Localized early
childhood
Skin vasculitis Yes 29 years Yes 10 years No No No No
Nasal septal perforation Yes 29 years Yes 6 years No Yes 49 years No No
Facial erythema Yes Yes Yes Yes Yes No
UV sensitivity Burns easily Burns easily Burns easily Urticaria Burns easily Burns easily
Alopecia at age of years Universalis 10 years Universalis 6 years Areata 7 years Totalis 4 years (grew
back) and universalis
30 years
No Universalis 10 years
(scalp hair grew
back) and universalis
12 years
Thyroid dysfunction No Hypo 12 years Hypo 7 years Hyper 38 years No Hyper 13 years
Autoimmune thyroiditis,
TpoAb
No Yes, 370 IU/mL No, <33IU/mL Yes, 610 IU/mL No Yes, 1855 IU/mL
Infection susceptibility
Skin infections Facial erysipelas 33
years, deep abscess
in right thigh 27 years
Necrotizing fasciitis
and abscesses in
upper extremity 3
years, necrotic
vasculitis and abscess
in the abdomen 10
years
No No Abscess in left
inguinum childhood
No
Periodontitis No No No No Yes 42 years Yes 30 years
Respiratory tract No Pneumonia 1.5 years No Recurrent sinusitis
adulthood
Recurrent sinusitis
adulthood
No
Genotype phenotype associations are highlighted.
0.2 mg/kg), with poor response. Vasculitis then responded well
to cyclosporine (maximum dose 250 mg/day, 2.5 mg/kg). A
subsequent sunburn however induced re-flaring of previous
ulcers. These subsided with topical corticosteroids. Additionally,
he has had Streptococcus pyogenes periobital cellulitis and a
single abscess on his inner thigh, but otherwise displays no
susceptibility to infections.
A single vasculitis ulcer recurred on his lower leg at age 37
year, after the STING p.Gly207Glu mutation had been identified.
In addition to a small oral prednisolone dose 0.2 mg/kg, he
was started on baricitinib 4 mg/day (0.03 mg/kg) increased to 6
mg/day (0.05 mg/kg) after 2 months. The ulcer had healed after
3 months treatment. After the initiation of baricitinib his overall
well-being had improved (with less fatigue and feeling ill) his hair,
eyelashes, and eyebrows had started to grow and the circulation
in his legs had improved. There was no visible change in the
livedo, facial erythema, or laboratory parameters. He continues
to receive oral baricitinib.
IV.1 has three children, of whom daughter V.2 shares a very
similar phenotype. Since birth, she has had cheek erythema and
severe livedo reticularis of extremities and trunk, most severe
on her thighs, upper arms, and sides. She has had UV-induced
urticaria. At age 6.8 years, she developed alopecia areata, which
progressed to universal alopecia with loss of all body hair except
the eyebrows and eyelashes by age 7.8 years. At age 12.5 years
she was diagnosed with autoimmune thyroiditis (TPOAb 370
IU/mL) and hypothyroidism. She has a nasal septal defect and
similar dysmorphic features as her father. At age 3 years, she
had S. pyogenes sepsis and necrotizing cellulitis on her upper
arm and abdomen. At age 10 years, she developed an eschar
on her abdomen, which developed rapidly into a large necrotic
abscess with S. pyogenes (Figure 1C). Surgical revision of the
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FIGURE 1 | G207E STING mutation associates with SAVI and lupus-like features. (A) Family pedigree. Prevalence of the G207E mutant allele is shown with + and –
signs, and individuals without in-depth clinical evaluation are denoted with gray dots; deceased individuals by diagonal bars. (B) Livedo reticularis in IV.1. (C,D)
(Continued)
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FIGURE 1 | Necrotizing cellulitis and vasculitis in V.2 initially (C), after surgical revision (D). (E) Vasculitis in IV.1’s skin with destructed vessels with neutrophils in their
walls and perivascular leukocytes and erythrocytes. (F) STING structure showing transmembrane (TM), dimerization, and cyclic-di-nucleotide (CDN) binding domains
and the carboxy-terminal tail. Previously identified mutations are denoted in red, the novel G207E mutation in purple. (G) Crystallographic structure of STING dimer in
complex with cGAMP (PDB entry 4EMT). G207 cannot contact cGAMP or polar (red) or hydrophobic (green) residues nearby, while E207 has a polar, flexible side
chain that can interact with polar amino acids and cGAMP.
necrotic and infected tissue produced a large wound on the
abdomen (Figure 1D). Skin biopsy from the edge of the necrosis
was indicative of small vessel vasculitis and underlying fasciitis.
She was successfully treated with i.v. antibiotics, prednisolone
(gradually tapered down from 0.5 mg/kg) and cyclosporine 100
mg/d (2.1 mg/kg). Treatment with negative pressure wound
therapy successfully assisted wound closure.
From birth, the mother of IV.1 (III.4), has had mild livedo
reticularis on the buttocks, thighs and upper arms. At age 7
years she developed alopecia areata and was diagnosed with
hypothyroidism. She burns easily in the sun and has constant
facial erythema.
III.7 developed livedo reticularis first on the buttocks at age
8 years, from where it spread to thighs and upper parts of shins,
upper arms, shoulders and stomach, and most recently on her
breasts. She also has facial erythema. The livedoid discoloration
continuously spreads and increases. She burns easily and had UV
intolerance as a child. She had early menopause at age 42 years
and since then has suffered from severe periodontitis.
IV.6 has had mild livedo reticularis form early childhood on
her upper arms and knees. She burns easily in the sun. At age
10 years she developed total alopecia and, has since lacked all
body hair while her scalp hair regrew within a few months. At
age 12 years, total alopecia reoccurred. She has occasionally also
had partial loss of eyelashes. At age 13 years, she was diagnosed
with autoimmune thyroiditis and hyperthyroidism. Anti-thyroid
peroxidase-antibody (TPOAb) titers reached 1,855 IU/mL at age
21 years. She was then also diagnosed with pituitary thyroid
resistance and received radioiodine treatment. Thereafter, she
has received thyroid hormone substitution. She has constantly
elevated calcitriol and calcium levels with normal parathyroid
hormone levels, not indicative of vitamin D resistance. However,
after initiating calcium and vitamin D- replacement therapy,
she has had minor regrowth of scalp hair. She has recurrent
periodontitis and tooth enamel defects. Despite exercise-induced
shortness of breath, lung function tests (spirometry and diffusion
capacity) were normal.
From adulthood, III.9 has had severe livedo reticularis, which
slowly progressed on her upper arms, posterior armpits, sides,
lateral back region, and buttocks extending to posterior thighs.
At age 4 years, she experienced total alopecia with subsequent
hair regrowth. During her childhood and adolescence, she had
recurrent, intermittent spells of alopecia areata. At age 30
years, total alopecia with sparsening of eyelashes reoccurred
and a vitiligo spot appeared on her cheek. At age 38 years,
she was diagnosed with autoimmune thyroiditis with TPOAb
levels >1,000 IU/mL. She has suffered from infertility that is
unresponsive to treatment. She has a nasal septal defect, but is
not sensitive to UV light. She has had recurrent sinusitis and sleep
apnea, while lung function tests were normal.
DNA Extraction
Genomic DNA was extracted from EDTA blood samples or
salivary samples using Qiagen FlexiGene DNA kit (Qiagen,
Valencia, CA, USA) or OraGene DNA Self-Collection Kit (OGR-
250, DNA Genotek, Holliston, MA, USA).
Genotyping and Linkage Analysis
The DNA samples of 10 family members were run on the
IlluminaHumanOmniExpressExome-8v1-2 array at the Science
for Life Laboratory SNP&SEQ platform in Uppsala, Sweden,
according to standard protocols (Illumina, San Diego, CA, USA).
Results were analyzed using Illumina GenomeStudio 2011.1
software. Two controls were run in parallel. Genotyping was
based on cluster files generated from the signal intensities from
more than 800 DNA samples processed in parallel to this project.
The Rutgers genetic map interpolator Rutgers Map v2 (26)
was used to attain genetic map information for the markers in
the linkage analysis. Merlin [v1.1.2 (27)] was used to perform
parametric and non-parametric linkage analysis, using the LD-
pruned genotype dataset.
Whole Genome Sequencing
Next generation sequencing libraries were built according to
established laboratory protocols at the Science for Life Laboratory
Stockholm and the Institute for Molecular Medicine Finland
(FIMM). The exome libraries were processed according to
the Agilent SureSelect Target Enrichment System (Agilent
Technologies, Santa Clara, CA, USA) for Illumina Paired-End
Sequencing Libraries (Illumina, San Diego, CA, USA) using
the SureSelect Human All Exon V5 capture library (Agilent
Technologies, Santa Clara, CA, USA). Libraries were sequenced
with 101 bp read length (HiSeq1500 sequencing platform,
Illumina, San Diego, CA, USA). The read mapping, variant
calling and genome annotation were performed as described
previously (28). We focused the search on the haplotype that
segregated with the phenotype, prioritizing rare, heterozygous
coding variants that negatively affect conserved residues and
shared by both whole genome sequenced individuals. Only
one such variant was identified, localized within the TMEM173
gene. The G207E variant was absent from all major public
[The Exome Aggregation Consortium (ExAC), 1,000 Genomes,
NHLBI Exome variant server and UK TWIN and ALSPAC study
cohorts (2–4)], as well as in-house databases.
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Targeted TMEM173 PCR Amplicon
Sequencing
Sample preparation was performed according to an in-house
targeted PCR amplification protocol. All oligonucleotides were
synthesized by Sigma-Aldrich (St. Louis, MO, USA). The
protocol includes two rounds of PCR amplification. Sequencing
of PCR amplicons was performed using Illumina MiSeq
instrument withMiSeq Control Software v2.5 (Illumina, Inc., San
Diego, CA, USA). Samples were sequenced as 251 bp paired-
end reads and two 8 bp index reads. The read mapping, variant
calling and genome annotation were performed as described
previously (28).
Peripheral Blood Immunophenotyping
Fresh EDTA-blood samples or peripheral blood mononuclear
cells (PBMCs) were used for B and T lymphocyte
immunophenotyping according to Haapaniemi et al. (28),
Ilander et al. (29). Evaluation of T cell responses is also described
in detail elsewhere (29).
Site-Directed Mutagenesis Predictions
The 3D structures of STING [4LOI and 4KSY; (30, 31)] were
extracted from Protein Data Bank [PDB; www.rcsb.org, (32)]
and the effects on the protein stability of the individual mutants
analyzed with SDM (33).
Construct Generation
The TMEM173 cDNA was obtained as a gateway compatible
entry-clone from human Orfeome collection (Horizon
Discovery, UK). All TMEM173 variant constructs were
created using Q5 Site-directed Mutagenesis Kit (New England
Biolabs, Ipswich, MA, USA). The mutagenesis primers are
listed in Supplementary Table IA. All the generated variant
entry-constructs were confirmed with direct sequencing prior to
introduction to C-MAC-Tag destination vector (34).
Luciferase Assay
HEK293 cells were cultured in complete DMEM (Sigma-Aldrich,
Espoo, Finland). 20,000 cells were seeded onto Costar 3610 white,
clear bottom 96-well plates, and the following day co-transfected
with 50 ng of TMEM173 constructs or empty C-MAC-tag-vector
(34), 40 ng of IFN-β promoter-driven firefly luciferase reporter
plasmid (IFN-β-pGL3; a kind gift from Yanick J. Crow), and
1.4 ng Renilla luciferase reporter plasmid (pRL-SV40) by using
FuGENE 6 (Promega, Madison, WI, USA). Transfected cells
were stimulated 24 h later with 4µg/ml 2′3′-cyclic guanosine
monophosphate (cGAMP), or 3′3′-cGAMP or c-di-GMP (all
Invivogen, SanDiego, CA, USA) by Lipofectamine 2000 (Thermo
Fischer Scientific, Vantaa, Finland) transfection. After 24 h
incubation, the cells were lysed with 1X passive lysis buffer
(Promega). Luciferase assays were performed with the Dual-Glo
Luciferase Assay System (Promega) according to manufacturer’s
instructions. For final results, counts of untransfected cells
were subtracted from both firefly and Renilla luciferase, and
firefly luciferase activity further normalized against Renilla
luciferase activity.
NanoString Analysis of Patient PBMCs
Blood samples were collected in Vacutainer R© CPTTM- tubes
(BD, New Jersey, USA) and PBMCs were isolated as instructed
by manufacturer. After RNA extraction, 100 ng RNA was
taken for NanoString (NanoString Technologies, Seattle, USA)
gene expression analysis. Our custom gene set containing
in total 50 genes included 45 IFN-regulated, inflammasome-
related, as well as JAK/STAT and NFκB signaling pathway
genes, and five housekeeping genes. As housekeeping genes
we used elongation factor 1-gamma (EEF1G), glyceraldehyde-
3-phosphate dehydrogenase (GAPDH), hypoxanthine-guanine
phosphoribosyltransferase (HPRT1), ornithine decarboxylase
antizyme 1 (OAZ1), and tubulin beta class 1 (TUBB). For
overnight hybridization at 65◦C, RNAs were mixed with 5′
reporter probes (tagged with fluorescent barcodes of targeted
genes) and 3′ biotinylated capture probes. Reactions were
purified and immobilized on the sample cartidge surface by
utilizing the Prep Station (NanoString Technologies), and the
cartridge was scanned in triplicate using an nCounter Digital
Analyzer (NanoString Technologies). Gene expression data was
analyzed with the nSolverTM 4.0 analysis software (NanoString
Technologies) performing two-step normalization using default
settings as recommended by the manufacturer. The normalized
values were utilized to calculate fold change for each individual
gene between patient and matched control. The median fold
change of all was used to calculate the interferon scores similarly
to Rice et al. (35).
Culture and Stimulation of PBMCs
PBMCs were isolated from fresh EDTA-anticoagulated blood
by density gradient centrifugation in Ficoll-Paque PLUS (GE
Healthcare, UK). After a minimum of 3 h rest in complete
RPMI 1640 (Lonza, Basel, Switzerland) cells were stimulated with
1µg/ml lipopolysaccharides (LPS) from E.coli O111:B4 (Sigma),
1µg/ml Pam3Cys-SKKKK (Pam3Cys) (EMC microcollections),
and 5mM ATP (stock solution neutralized; Sigma) for the
indicated times.
Measurement of Cytokine Secretion
TNF-α and the mature, cleaved forms of IL1β and IL18 were
detected from PBMC culture media supernatants using Human
TNF-α DuoSet ELISA, Human IL1β/IL1F2 DuoSet ELISA, and
Human Total IL18 DuoSet ELISA (all from R&D Systems).
Quantitative Real-Time PCR
PBMC RNA was isolated using the RNeasy Plus Mini Kit
(Qiagen), followed by cDNA synthesis with iScript kit (Bio-Rad).
Quantitative real-time PCR was run in duplicate reactions of 10
ng cDNA using LightCycler480 SYBR Green I master (Roche
Diagnostics, Espoo, Finland) and a LightCycler96 instrument
(Roche). See Supplementary Table IA for primer sequences.
Relative gene expression was calculated using the 2(−11Ct)
method. The data was normalized against geometric mean of
expression of two housekeeping genes (ribosomal protein lateral
stalk subunit P0 and beta-2-microglobulin).
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Cell Culture
To generate stable, isogenic, inducible cell lines Flp-InTM
T-RExTM HEK293 cells (Invitrogen, Life Technologies) were
transfected with the generated STING-MAC-tagged constructs
using FuGENE6 (Promega) as described earlier (36). Cells
were cultured as instructed by manufacturer. Five 14 cm plates
for each construct and biological replicate were induced with
1µg/ml tetracycline and 50µM biotin 24 h prior to harvesting.
Harvesting, cell lysis, affinity-purification, mass spectrometry
were performed as described (34, 36).
Mass Spectrometry Filtering and Data
Analysis
The mass spectrometric data was searched with Proteome
Discover 1.4 (Thermo Fischer Scientific) using the SEQUEST
search engine against theUniProtKB/SwissProt human proteome
(http://www.uniprot.org/, version 2015-09). Search parameters
were set as in Liu et al. (34). All data were filtered to
high-confidence peptides according to Proteome Discoverer
FDR 1%. The lists of identified proteins were conventionally
filtered to remove proteins that were recognized with <2
peptides and two PSMs. The high-confidence interactors were
identified using SAINT and CRAPome as in Liu et al.
(34). Each sample’s abundancy was normalized to its bait
abundancy. These bait-normalized values were used for data
comparison and visualization. The bait-normalized values from
BioID data obtained from previous step were used as input
for MS microscopy analysis (http://www.biocenter.helsinki.fi/bi/
protein/msmic) (34). MS microscopy calculates a localization
score that numerically describes the bait protein’s dynamic
localization in cell.
Statistics
Statistical analysis using 2-tailed Student’s t-test was
performed using Microsoft Excel. A p-value less than 0.05
was considered significant.
RESULTS
Clinical Presentation and Immune
Phenotype
We evaluated a multigenerational Finnish family with SAVI-
like features and multiple symptoms previously not associated
with SAVI or chilblain lupus (Supplementary Figure 1A). Six
out of ten affected family members were available for detailed
clinical evaluation (Figure 1A), the main clinical findings are
summarized in Table 1. Affected family members suffered from
photosensitivity, alopecia ranging from areata to universalis
and autoimmune thyroiditis with elevated thyroidperoxidase
antibodies (TPOab) (Table 1). Prominent features included
early-onset persistent livedo reticularis, skin vasculitis, recurrent,
and severe infections variably reported in SAVI (Figures 1B–E).
None had typical SAVI associated interstitial lung disease,
violaceus facial, nasal, auricular or acral patches, ulcers or
necroses, febrile attacks, failure to thrive, elevated inflammatory
markers, or lupus autoantibodies (Supplementary Figure 1A;
Supplementary Table IIA). The most severely affected suffered
fromUV induced cutaneous vasculitis, nasal septum perforation,
severe infections including necrotizing cellulitis, and abscesses
concomitant with SAVI (Table 1; Supplementary Figure 1A).
Immunological workup is shown in Supplementary Table II.
All six evaluated patients had increased peripheral CD4+
T cell and naïve CD4+CCR7+CD45RA+ T cell count
(Supplementary Table IIB). The central memory CD4+ T
cells numbers remained unaffected, but pronounced decreases
were observed in the effector memory subset. These observations
are in accordance with findings on patients carrying activating
TMEM173 mutations (37). Among B cell populations, both
naïve (CD27−IgD+) and immune-exhausted activated
(CD38lowCD21low) B cells were increased in 4/6 patients
(Supplementary Table IIB). Acute phase reactants, blood cell
counts, various autoantibodies, and complement activation were
normal (Supplementary Table II).
Identification and Structural Analysis of
TMEM173 Mutation
The pedigree (Figure 1A) indicated autosomal dominant
inheritance. We performed linkage analysis on 12 unaffected
and 6 affected family members and whole genome sequencing
on patients IV.1 and V.2. Non-parametric linkage scores of >1.7
were observed at four loci on chromosomes 3, 5, 9, and 12. We
filtered the data for shared coding mutations not present in
control databases (The Exome Aggregation Consortium (ExAC),
1,000 Genomes, NHLBI Exome variant server and UK TWIN
and ALSPAC study cohorts (2–4), as well as in-house databases).
This analysis recovered, in these four candidate loci, only one
co-segregating variant which was not present in the healthy
controls, was evolutionary conserved and which was predicted
to damage protein structure.
This heterozygous missense mutation Chr5 (GRCh38):
g.139478409C> T results in a p.Gly207Glu (G207E) substitution
in STING, and was absent from major public and in-house
genome databases. Using the online Combined Annotation
Dependent Depletion (CADD) predictor (https://cadd.gs.
washington.edu/snv) value 17 is obtained for the variant
suggesting mild-to-moderate damaging effect. However, the
in-silico predictions of the causality of mutations is extremely
challenging and different prediction algorithms do rarely agree.
Therefore, we set to analyze the effect of G207E more carefully
using structural biology and biochemistry methods.
The protein fold of G207E mutation participates in substrate
binding and STING folding. Based on protein structure
prediction, G207E likely changes the electric charge of the fold,
destabilizes it and potentially alters its function (Figures 1F,G,
Supplementary Table IB). The G207E localizes next to a
previously described mutation p.Cys206Tyr (C206Y) (14).
To compare C206Y and G207E, we predicted the effects
of single residue changes on protein structure and stability
using Site Directed Mutator (SDM) (33). SDM predicted that
both C206Y and G207E reduce the stability of the protein
(pseudo 11G −1.27/−1.28 and −0.72/−0.63, respectively,
Supplementary Table IB) and likely lead to protein malfunction
and disease. The C206Y mutation with newly acquired aromatic
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side chain results in more drastic structural alteration than
G207E. Although the C206Y mutation received higher SDM
score, the C206Y-associated phenotype is not very severe. This
could be due to the limitations of the in silico predictions
algorithms, which promotes the use of biochemical/cell biological
experimentation for deciphering the causality of a mutation–
and/or that addional risk alleles are involved and modulate the
patient phenotypes.
Identification of Polymorphisms in
TMEM173 and IFIH1
Arginine (R) at position 232 has been identified as a major allele
of human STING in the general population, albeit histidine (H)
232 is commonly listed as the wildtype allele (6). In accordance
with the population data, the majority of the affected family
members were heterozygotes for R232 (Table I). Homozygous
H232 was found only in late onset livedo and recurrent sinusitis
in adulthood.
A shared haplotype of two common IFIH1 variants
(rs1990760, A946T, and rs3747517 H843R) cause constitutively
active IFN signaling and pre-disposition to autoimmune diseases
(20, 23, 24). In the affected family four of six analyzed members
(IV.1, V.2, III.4, III.9) had at least one copy of the IFIH1 T946
risk allele, and were also homozygous for the second 843R
risk variant (Table 1). In accordance to literature (25), these
individuals did not have periodontitis, while the carries of A946
and H843 (III.7, IV.6) did (Table 1). Homozygosity for IFIH1
T946 and R843 was associated with severe deep infections in V.2.
Overall, based on the clinical presentations of the affected family
members and their combined genotypes of the monogenic
TMEM173 mutation G207E, R232H variants, as well as the
presence of the IFIH1 risk alleles T946 and R843, we propose
that TMEM173 and IFIH1 can jointly promote disease from
207E/H232/AA/HH toward 207E/R232/TT/RR (Table 1).
G207E Mutation in STING Constitutively
Activates IFN-β, STAT1/2, STAT3, and NFκB
Transcription
To study the effect of STING mutations on activation of
IFN-β, STAT1/2, STAT3, and NFκB pathways, we utilized
luciferase-based reporter assays. The constitutively active STING
p.Ans154Ser (N154S) SAVI mutant was used as a positive control
(5). To mimic the combined genotypes of the affected family
members, we combined the G207E mutation with variants R232
(genotype of patients IV.1, V.2, III.4, IV.6; herein R+207E)
or H232 (genotype of patients III.9, III.7; herein H+207E).
Both combinations clearly activated IFN-β, STAT1/2, and STAT3
pathways, even in unstimulated state (Figures 2A–C), thus
indicating 207E as a GOF mutation.
The patients were susceptible to bacterial infections, but only
a few remembered ever having viral infections. After stimulation
with 2′3′-cGAMP (mimicking the mammalian response to
cytosolic viral DNA) or bacterial second messengers c-di-GMP
and 3′3′-cGAMP (6, 38) R+207E presented slight pathway
activation in IFN-β and STAT1/2, while H+207E remained
constant (IFN-β) or diminished (STAT1/2) (Figures 2A,B).
These results further confirm the crucial role of R232 in cGAMP
binding and IFN induction (30, 39). Both R/H+207E induced
STAT3 pathway, as well as ligand-dependently hyperactivated
NFκB pathway (Figures 2C,D).
We next analyzed IRF3 (Ser386) phosphorylation in stable
HEK293 cells (Figure 2E). Interestingly, IRF3 phosphorylation
remained at low levels in all combinations and their single
counterparts, while N154S showed markedly elevated
phosphorylation (Figure 2E). In concordance with our data,
IRF3 independent disease development was reported in a STING
N153S mouse model (40), demonstrating the involvement and
activation of multiple pathways in STING-associated disease.
Baseline Expression of Interferon
Signature Genes and JAK/STAT Pathway
Components Are Elevated in Patients With
G207E Mutation
To directly analyze baseline gene expression in patient PBMCs,
we designed a customNanoString (41) gene set targetingmultiple
IFN-inducible and IFN signaling-related genes, as well as genes of
the NFκB-regulated inflammasome pathway (Figure 3A). Strong
upregulation of IFN-regulated genes was detected in an unrelated
Singleton-Merten-patient with dominant GOF IFIH1 mutation,
validating the gene set and analysis pipeline (Figure 3A). The
more severely affected G207E patients (IV.1, V.2, III.4) with both
IFIH1 risk alleles T946 and R843 displayed higher IFN-regulated
mRNA levels (marked in red) than the patient (III.7) with G207E
mutation and one allele of IFIH1 R843 (Figure 3A).
For IFN signature analysis (Figure 3B) we selected seven
genes (IFIT1, ISG15, RSAD2, SIGLEC1, IFI27, IFI44, and IFI44L)
based on previous publications (13, 35). We noted different
gene expression pattern and elevated IFN scores in patients with
G207E mutation and both IFIH1 risk alleles (Figure 3B). The
patient without IFIH1 T946 and carrying one allele of R843
showed fold changes equal to healthy controls.
PBMCs displayed no clear overall tendency of baseline levels
of inflammasome-related genes, whereas JAK/STAT-pathway
components were modestly upregulated, and selected NFκB-
related genes, including the key negative regulator NFκBIA, were
downregulated (Figures 3C–E). The above speculated trend of
additive effects of genetic variance was most pronounced with
STING downstream targets JAK1, JAK3, STAT4, STAT6, and IL6,
where patient V.2 presented the highest baseline gene expression
levels (Figures 3D,E).
Baricitinib treatment clearly reduced the expression of IFN-
inducible and IFN signaling-related genes in patient IV.1
(Supplementary Figure 1B). None of the other patients received
immunosuppressive therapies during the time of evaluation.
Enhanced Type I Interferon Response and
Aberrant Inflammasome Activation in
Patients With G207E Mutation
STING has been recently linked with activation of the NLRP3
inflammasome (42, 43), which can be activated either by the
canonical, non-canonical, or alternative pathway (44). To test
inflammasome hyperactivation, we stimulated patient PBMCs
with LPS and a subsequent ATP pulse or with prolonged
LPS alone to activate the canonical and alternative pathways,
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FIGURE 2 | G207E constitutively activates several signal transduction pathways in HEK293 cells. Luciferase activities of (A) IFN-β, (B) STAT1/2, (C) STAT3, or (D)
NFκB—reporters after transient transfection with empty vector (mock), H232, R232, H + 207E, R + 207E or SAVI mutant N154S. Expression of the constructs was
(Continued)
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FIGURE 2 | verified by anti-HA antibody. Through A-C, the cells were stimulated with 4µg/ml CDNs for 24 h or left unstimulated. For NFκB reporter assay, the cells
were stimulated with 10 ng/ml TNF-α for 16 h. In all the (A–D) mean of minimal three replicates together with SEM is presented. Statistical significance is indicated with
asterisk (*p < 0.05, **p < 0.01, ***p < 0.001; paired t-test). (E) The baseline levels of IRF3 phosphorylation remained unaltered in H232, H + 207E, R232, R + 207E.
Only N154S presented elevated phosphorylation of IRF3.
respectively. The secretion of IL1β and IL18 was used as a proxy
for inflammasome activation. Pam3Cys that activates NFκB
pathway via Toll-like receptor (TLR) 1/2, but does not normally
trigger inflammasome signaling or type I IFN response, was used
as a control (45). In the patients’ PBMCs LPS induced stronger
secretion of mature IL1β and IL18 via the alternative NLRP3
inflammasome pathway (Figures 4A,B) and, importantly, IL1β
secretion was aberrantly triggered by Pam3Cys (Figure 4A).
The NFκB-mediated induction of pro-IL1β mRNA was higher
in patients’ PBMCs after LPS and Pam3Cys stimulation
(Supplementary Figures 2A,B), which may contribute to
elevated IL1β secretion. However, only LPS but not Pam3Cys
triggers signaling via TRIF adapter molecule that is required
for activation of alternative NLRP3 inflammasome pathway
and subsequent proteolytic maturation of IL1β/IL18 (45). This
suggested that the enhanced cytokine secretion in patients’
PBMCs was primarily driven by altered signaling rather than
elevated mRNA levels. As the patients’ PBMCs showed normal
IL1β/IL18 responses to ATP stimulation after short priming
(Figure 4D; Supplementary Figure 2C), the mutant STING
mainly targeted alternative NLRP3 inflammasome signaling.
LPS also induced a stronger type I IFN response in the
patients’ PBMCs (Figure 4C). In line with this, alternative
NLRP3 inflammasome pathway and type I IFN response both
utilize a TRIF-dependent signaling pathway downstream LPS
(45). Conceivably, constitutive type I IFN activity driven by
mutant STING could involve activation of a signaling molecule
shared with the alternative NLRP3 inflammasome pathway,
enabling also Pam3Cys-triggered IL1β secretion. The patients
also showed elevated TNF-α response to LPS, confirming a wide
dysregulation of TLR responses, including NFκB (Figure 4E;
Supplementary Figure 2B). However, we did not see a general
correlation between clinical disease severity and cytokine
secretion (Figures 4A,B,E).
Molecular Context of Mutant STING
To characterize the molecular context of STING at near
physiological levels (46), we analyzed the protein-protein
interactions of H232 (wild-type; wt), I200N [null mutant (47,
48)], N154S (5), and H+207E in inducible HEK293 cells
using BioID proximity labeling (49). The BioID-method tags
the protein of interest (bait) with a modified biotin ligase,
which adds biotin to the closely interacting proteins (preys)
(49). The biotinylated proteins are then affinity-purified and
analyzed with quantitative mass spectrometry. In line with
previous data (39), the wt STING preferentially interacted with
Golgi, ER, endosomal and mitochondrial proteins (Figure 5A).
I200N, G207E, and N154S lost multiple interactions compared
to the wt. Hierarchical clustering of the interactions of the
mutants form a continuation from the null allele (I200N) to
GOF SAVI mutant (N154S), showing G207E between the wt
and the N154S (Figure 5A). This result is consistent with the
reporter assay data and milder clinical phenotype in G207E
carriers (Figure 2).
We utilized mass spectrometry microscopy (MS microscopy)
(34) on our steady state BioID data. The resolution of MS
microscopy outperforms fluorescent microscopy in refining the
subcellular location (34), and showed I200N localization mainly
to ER, while G207E, N154S, and wt were predominantly localized
to Golgi (Figure 5B). Fascinatingly, the G207E localized more
to the ER than wt or N154S (localization scores 0.86, 0.66,
and 0.58, respectively; Figure 5B). It could be speculated that
G207E mutant protein induces ER stress and is more rapidly
degraded than WT or N154S STING –however, this is not
visible in the WB- or MS analyses of the patients’ PBMCs or
transgenic HEK293 cell lines expressing the different STING
mutants, respectively (Supplementary Figures 3A,B).
To gain in-depth information of G207E, we analyzed
its interactome in both allelic backgrounds (H/R + 207E).
Generally, the G207E mutation led to a reduction of protein-
protein interactions with the proteins residing in Golgi, ER,
endosome and mitochondria, compared to the corresponding wt
(Figure 5C). Notably, the G207E mutant had weak interactions
with all components of the coatomer complex I (COPI)-
machinery mediating retrograde transport from Golgi to
the ER (50, 51) (Figures 5A,C). Also, multiple components
of the coatomer complex II responsible for ER to Golgi
transport [syntaxin 5 (STX5)], protein transport protein
Secs (Sec23A, Sec23B, Sec24A, Sec24B) were downregulated
(Figures 5A,C). The interactions between GOGB1 and UBIA1
were stronger in the H+207E mutant (>two-fold). UBIA1
localizes to ER-Golgi compartment, while GOGB1 mainly
resides at the cis-Golgi participating in COPI-mediated
transport (52–54). Comparison of interactions between
R+207E and H+207E showed clear differences in five
genotype-specific interactions (Supplementary Figure 3C).
R+207E lost association with APMAP (adipocyte plasma
membrane-associated protein with uncharacterized function),
but interacted more with PDXD1 (pyridoxal-dependent
decarboxylase domain-containing protein 1) and RFA1
(Replication protein A 70 kDa DNA/binding subunit) compared
to H+ 207E.
These data suggest that in addition to amplifying downstream
signaling, the STING GOF mutations cause broad alterations
in subcellular localization and plausibly defective vesicular
trafficking. The features overlap with other known monogenic
autoimmune diseases that are caused by defects in the
vesicular trafficking (55, 56). The alterations likely contribute
to the autoimmune and infectious manifestations seen in the
affected patients.
Frontiers in Immunology | www.frontiersin.org 10 December 2019 | Volume 10 | Article 2770
Keskitalo et al. TMEM173 and Disease Modifying Alleles
FIGURE 3 | Gene expression analysis of patient PBMCs reveals alterations in IFN-regulated genes and multiple signaling pathways. (A) Heat map of baseline gene
expression of a custom Nanostring gene set in PBMCs of four G207E patients, a Singleton-Merten syndrome patient (SMS-pat; another type I interferon-mediated
(Continued)
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FIGURE 3 | disease), and three healthy controls. After background thresholding and normalization, agglomerative clustering was performed on z-scores of genes.
IFN-regulated genes are marked in red. (B) mRNA fold changes of seven IFN-regulated genes (IFIT1, ISG15, RSAD2, SICLEC1, IFI27, IFI44, and IFI44L) and the
resulting IFN score for each patient. (C–E) Fold changes in unstimulated patient PBMCs of inflammasome (C), JAK/STAT pathway (D), and NFκB pathway (E) related
genes. Fold change 1 and 4 are indicated with green and blue dotted lines, respectively. Through (A–E) mean of three measurements together with SD is presented.
DISCUSSION
We report a large family with a distinct somewhat lupus-like
and SAVI-like phenotype carrying a novel G207E mutation
in the substrate binding domain of STING. We propose
that the variance in disease severity in this family results
from a combinatory additive effect of coding polymorphisms
in TMEM173 and IFIH1 genes. The disease retained some
typical characteristics of SAVI e.g., cutaneous vasculitis, severe
infections including necrotizing cellulitis, exacerbation of skin
symptoms by cold and nasal septum defects (5, 11, 14),
but was considerably milder and lacked early onset lung
manifestations, violaceus, and ulcerative skin lesions, febrile
attacks and elevated inflammatory and autoinflammatory
markers (Supplementary Figure 1A). Instead, our patients
presented with several previously unreported STING-associated
lupus-like features including alopecia, photosensitivity, and
thyroid dysfunction. Most of them had marked and widespread
livedo reticularis from birth. Furthermore, their IFN score was
less severely elevated.
Consistent with SAVI patients (5, 37), all our patients had
expanded population of naïve CD4+ and CD8+ T-cells but low
numbers of mature B and T cells. STING has also been proposed
to act as an inhibitor of immune cell proliferation (37), an effect
linked to NFκB activation and spatially limited to Golgi (37). This
finding is supported by our data, which shows hyperactivation of
NFκB in the patient cells, and also an altered localization of the
G207E mutant within the Golgi/ER compartment.
As there is considerable variety in disease severity among the
TMEM173 mutant carriers (5, 11, 13–15), we further analyzed
the effect of common polymorphisms in TMEM173 (p.R232H)
and IFIH1 (p.A946T and p.H843R) on disease phenotype. As
note, all genotyped patients were negative for the HAQ allele
(R71H-G230A-R293Q). Patients with the R232 variant had more
severe symptoms. In vitro, this polymorphism strengthened
the enhanced activation of the mutant STING, leading to the
overexpression of STING downstream targets IFN, IL1β, and
IL18. The observation is consistent with previously reported
effect of R232 on amplifying IFN-β pathway activation in vitro
(6). We also noted a trend of additive clinical effect for the G207E
mutant and the three polymorphisms, with the combination
R232+G207E+IFIH1 T/T+R/R leading to a severe early-onset
phenotype that resembles the SAVI-features (Pat V.2). These
IFIH1 risk alleles have been shown to promote disease through
a combinatorial effect (24). Although supported by experimental
data, the effects need validation in larger patient sets.
Understanding of the crosstalk between STING-pathway and
the NLRP3 inflammasome controlling IL1β and IL18 secretion
is expanding, and recently STING was shown to have a role
in inflammasome activation (42, 43). We observed aberrant
alternative NLRP3 inflammasome activation in response to
bacterial TLR stimuli in the patient PBMCs. The constitutively
active STING-signaling in our patients’ PBMCs could explain
the elevated LPS-induced IL1β secretion and drive the observed
aberrant inflammasome activation utilizing an adaptor protein
TRIF (45, 57). Indeed, LPS was reported to aberrantly induce
IL1β secretion in STING V155M expressing TRIF−/− monocytic
cells (42). Activation of NLRP3 inflammasome has a key role
in the pathogenesis of other autoinflammatory diseases, such
as cryopyrinopathies (58). Our data suggests that dysregulation
of both interferons and IL1β may contribute to the disease
phenotypes of interferonopathies.
To our knowledge, our study is the first to define the
molecular interactions of STING. The majority of STING
partners were Golgi, ER or endosomal proteins, consistent
with reports of subcellular localization of STING (8, 39). The
monogenic GOF mutants N154S and G207E led to reduction
of interactions. Striking difference between N154S and G207E
are the weakened or lost interactions of G207E with COPI
and COPII complexes, essential for protein transport between
ER and Golgi (59). Loss of COPI also causes monogenic
autoimmune disease (56). The increased G207E interactions
included Sequestosome-1 (SQSTM) an autophagy receptor
involved in endosome organization (60). The combined loss of
COPI and gained SQSTM interactions together with aberrant
subcellular localization suggest impairment in mutant STING
trafficking. Since STING has been shown to predominantly
signal from endosomes, the impaired trafficking likely leads to
prolonged signaling and activation of downstream pathways
(59, 61). Interaction with AP-1 complex subunit beta-1 (AP1B1),
a protein involved in cargo sorting at trans-Golgi network, was
lost or diminished in both H + 207E and R + 207E, further
supporting the model of defective transport.
The interactomes of G207E in polymorphic backgrounds
(H232 and R232) were highly similar. The R + G207E
variant, which is associated with severe clinical disease,
further diminished the G207E interactions with the COPI
proteins—likely exaggerating the trafficking defect, and further
prolonging STING signaling from the endosomes. R + 207E
variant also associated more with ubiquitin carboxyl-terminal
hydrolase CYLD, which regulates inflammation and immune
responses via NFκB-inducing pathways (62–64).
To conclude, we describe in a multigenerational family a
novel STING mutation G207E as a cause for a combination of
SAVI-associated vasculopathy and selected lupus-like features.
We suggest that TMEM173 polymorphism p.R232H as well
as IFIH1 autoimmune risk variants p.A946T and p.H843R
might act as cumulative disease modifiers contributing to the
disease severity. However, more patients are needed to further
investigate this phenomenon. Treatment with JAK1/2 inhibitor
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FIGURE 4 | Type I interferon response and NLRP3 inflammasome activation in patient PBMCs. (A,B) Secretion of IL1β and IL18 in PBMC culture supernatants after
activation of NLRP3 inflammasome via the alternative pathway using prolonged LPS or Pam3Cys (P3C) stimulation. (C) RT-PCR analysis of IFNB1, IFIT2 and MX1 in
patient PBMCs untreated and after LPS treatment. (D) Secretion of IL1β in PBMC supernatant after canonical inflammasome pathway activation with LPS or
Pam3Cys priming followed by ATP stimulation. (E) TNF-α concentration in PBMC culture supernatants after LPS stimulation. The data collection in (A,B) and (D,E)
was performed with enzyme-linked immunosorbent assay (ELISA). Data are presented from three patients and three control subjects. Cytokine levels represent means
and the error bars denote SD from two biological replicates per condition; for RNA isolation and qPCR, the cells from these replicates were pooled.
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FIGURE 5 | Functional data of STING wt and mutant cell lines shows differences in genotypes. (A) Bait expression normalized relative amount of identified interacting
proteins (preys) in stable I200N (null mutant), H232 (wt), G207E, and N154S 293 cells. Dot size indicates relative prey abundance. (B) Mass spectrometry microscopy
(Continued)
Frontiers in Immunology | www.frontiersin.org 14 December 2019 | Volume 10 | Article 2770
Keskitalo et al. TMEM173 and Disease Modifying Alleles
FIGURE 5 | assigned localizations at steady state. Localization abbreviations denote the following compartments: peroxisome (PER), microtubule (MIC), endosome
(ED), proteasome (PRO), nuclear envelope (NE), Golgi (GOL), lysosome (LYS), nucleolus (NUC), plasma membrane (PM), endoplasmic reticulum (EM), mitochondria
(MIT), centrosome (CEN), chromatin (CHR), and exosome (EXO). Color gradient indicates localization score. (C) Identified proteins and their fold changes in H + 207E
and R + 207E compared to their wild-type counterparts. The light gray area indicate fold change 0–0.5, and dotted line fold change equal to 1.
baricitinib was beneficiary in one patient. We also describe
the interactomes of wt and mutant STING, demonstrating a
localization defect in the latter, and report elevated NRLP3
inflammasome activation and IL1β secretion in patient PBMCs,
potentially contributing to the disease phenotype. The results
broaden the clinical spectrum of STING mutation phenotypes,
and increase understanding of the molecular mechanisms of
nucleic acid-driven inflammatory diseases.
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